摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(S)-camphor sulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole

中文名称
——
中文别名
——
英文名称
1-(S)-camphor sulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole
英文别名
(R)-camphor sulfonyl-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole;(1S,4R)-1-[[5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-yl]sulfonylmethyl]-7,7-dimethylbicyclo[2.2.1]heptan-2-one
1-(S)-camphor sulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole化学式
CAS
——
化学式
C27H33N3O6S2
mdl
——
分子量
559.708
InChiKey
LOVMHHMMURDXAC-HWVLWZQMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    38
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    145
  • 氢给体数:
    0
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] A NOVEL STEREOSELECTIVE SYNTHESIS OF BENZIMIDAZOLE SULFOXIDES<br/>[FR] NOUVEAU PROCEDE DE SYNTHESE STEREOSELECTIVE DE SULFOXYDES DE BENZIMIDAZOLE
    申请人:HETERO DRUGS LTD
    公开号:WO2005116011A1
    公开(公告)日:2005-12-08
    The present invention relates to a process for stereoselective synthesis of substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole is reacted with (R)-camphorsulfonyl chloride to form a mixture of 1-(R)-camphorsulfonyl-5-(and 6-)methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-1H-benzimidazole, oxidized to obtain a diastereomeric excess of 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole over 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(R)-sulfinyl]-1H-benzimidazole, the diastereomers are separated by fractional crystallization and the separated 1-(R)-camphorsulfonyl-(5- and 6-)-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1H-benzimidazole is deprotected to give esomeprazole.
    本发明涉及一种对取代磺醚进行立体选择性合成的方法,可以得到单一对映体或对映富集形式的取代磺醚。因此,5-甲氧基-2-[[(4-甲氧基-3,5-二甲基-2-吡啶基)甲基]硫基]-1H-苯并咪唑与(R)-樟脑磺酰氯反应,形成1-(R)-樟脑磺酰基-5-(和6-)甲氧基-2-[(3,5-二甲基-4-甲氧基-2-吡啶基)甲基硫基]-1H-苯并咪唑的混合物,氧化以获得1-(R)-樟脑磺酰基-(5-和6-)甲氧基-2-[(3,5-二甲基-4-甲氧基-2-吡啶基)甲基-(S)-亚硫基]-1H-苯并咪唑的对映体过量,相对于1-(R)-樟脑磺酰基-(5-和6-)甲氧基-2-[(3,5-二甲基-4-甲氧基-2-吡啶基)甲基-(R)-亚硫基]-1H-苯并咪唑,这些对映体通过分级结晶分离,分离的1-(R)-樟脑磺酰基-(5-和6-)甲氧基-2-[(3,5-二甲基-4-甲氧基-2-吡啶基)甲基-(S)-亚硫基]-1H-苯并咪唑去保护得到埃索美拉唑。
  • [EN] A PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE ESOMEPRAZOLE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ÉSOMÉPRAZOLE PUR SUR LE PLAN ÉNANTIOMÈRE
    申请人:HETERO DRUGS LTD
    公开号:WO2009040825A1
    公开(公告)日:2009-04-02
    The present invention provides an improved and commercially viable process for preparation of substantially enantiomerically pure esomeprazole in neutral form or as a pharmaceutically acceptable salt or as its solvates including hydrates. Thus, for example, a compound containing a mixture of 1-(S)-camphorsulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1 H-benzimidazole and 1-(S)-camphorsulfonyl-6-methoxy-2-[(3,5- dimethyl-4-methoxy-2-pyridyl)methyl-(S)-sulfinyl]-1 H-benzimidazole is hydrolyzed with barium hydroxide, isolated the resulting esomeprazole barium salt followed by neutralization with an acid to yield substantially enantiomerically pure esomeprazole in neutral form and then converted into its pharmaceutically acceptable salts.
    本发明提供了一种改进的商业化制备方法,用于制备中性形式或其药学可接受盐或其溶剂包括水合物的近乎对映纯的埃索美拉唑。例如,将含有1-(S)-蒎磺酰基-5-甲氧基-2- [(3,5-二甲基-4-甲氧基-2-吡啶基)甲基-(S)-亚砜基] -1H-苯并咪唑和1-(S)-蒎磺酰基-6-甲氧基-2- [(3,5-二甲基-4-甲氧基-2-吡啶基)甲基-(S)-亚砜基] -1H-苯并咪唑的混合物通过氢氧化钡水解,隔离得到所得的埃索美拉唑钡盐,然后通过酸中和得到近乎对映纯的中性形式的埃索美拉唑,然后转化为其药学可接受的盐。
  • OPTICAL PURIFICATION OF ESOMEPRAZOLE
    申请人:Parthasaradhi Reddy Bandi
    公开号:US20110213155A1
    公开(公告)日:2011-09-01
    The present invention relates to process for optical purification of esomeprazole or a salt thereof. Thus, esomeprazole sodium having 20 to 1% R-omeprazole by weight of the sum of the contents of esomeprazole and R-omeprazole is precipitated from a solvent selected from an alcohol or a mixture of alcohols and the precipitated solid is collected to obtain optically pure esomeprazole sodium.
    本发明涉及一种对埃索美拉唑或其盐进行光学纯化的方法。因此,从醇或醇混合物中选择的溶剂中沉淀出含有20至1%R-奥美拉唑的埃索美拉唑钠,其重量为埃索美拉唑和R-奥美拉唑含量之和,并收集沉淀固体以获得光学纯的埃索美拉唑钠。
  • Novel process for substituted sulfoxides
    申请人:Parthasaradhi Reddy Bandi
    公开号:US20060089386A1
    公开(公告)日:2006-04-27
    The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole.
    本发明涉及一种制备取代亚砜的方法,可以制备单一对映体或对映富集形式。因此,将外消旋奥美拉唑与(S)-樟脑磺酰氯反应,形成一种二对映异构体混合物,然后通过分级结晶分离二对映异构体,接着去保护基得到左旋奥美拉唑。
  • NOVEL SUBSTITUTED SULFOXIDES
    申请人:REDDY Parthasaradhi Bandi
    公开号:US20070129406A1
    公开(公告)日:2007-06-07
    The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole.
    本发明涉及一种制备取代亚砜的过程,可以制备单一对映体或对映富集的形式。因此,将混合的奥美拉唑与(S)-樟脑磺酰氯反应形成一种非对映异构体混合物,然后通过分馏结晶分离这些非对映异构体,随后去保护作用得到埃索美拉唑。
查看更多